Industry: EMA Should Use Real-World Evidence to Track Drug Safety

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency should focus on real-world evidence and big data to assess the impact of the agency’s pharmacovigilance activities on industry.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor